-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
news
newsYesterday, the "Lancet" magazine published the Phase III clinical results of an old antidepressant drug fluvoxamine in the treatment of new crowns
.
This trial called TOGETHER screened 9803 patients with severe new coronary disease, and was terminated early due to its excellent efficacy
Drug source analysis
Drug source analysisFluvoxamine is an old drug with an expired patent.
It is said that even if it is used in the hospital for 10 days, it only costs $4
.
An anti-depressant serotonin inhibitor (SSRI), travel long distances to fight the new crown, what is this spirit? One theory is that fluvoxamine can inhibit the combination of platelets and serotonin to slow down thrombosis, thus reducing the cardiotoxicity caused by the new crown
But suspicion is suspicion, fluvoxamine may really be effective
.
Previously uncontrolled trials have shown that this old drug does have the effect of controlling the new crown, and now there are two ongoing controlled trials in the United States
Because the new crown is coming fiercely and the pharmaceutical industry does not have enough time to systematically develop new drugs, new use of old drugs has become a major strategy
.
Unfortunately, antiviral drugs are not the focus of the modern pharmaceutical industry, so although in vitro screening of antiviral drugs is relatively easy, there are not many approved antiviral drugs available for screening
Severe COVID-19 complications are an immune disease, and there are many more marketed drugs that regulate the immune system than antiviral drugs, but the in vitro screening of immunomodulators and even animal experiments are also much more complicated
.
Because of the tight time limit, clinical trials have actually become the only screening mode.
